C12N 2310/332
Abasic residue
C12N2310/332 (Abasic residue) appears on 199 US grants and 413 published applications in this corpus.
Search patents in C12N- Granted patents
- 199
- Published applications
- 413
- Assignees
- 76
- Inventors
- 420
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 7 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 6 | 0 |
| 2001 | 6 | 1 |
| 2002 | 6 | 11 |
| 2003 | 5 | 33 |
| 2004 | 4 | 21 |
| 2005 | 2 | 65 |
| 2006 | 4 | 10 |
| 2007 | 1 | 9 |
| 2008 | 1 | 8 |
| 2009 | 3 | 26 |
| 2010 | 7 | 11 |
| 2011 | 13 | 12 |
| 2012 | 7 | 6 |
| 2013 | 7 | 16 |
| 2014 | 4 | 7 |
| 2015 | 9 | 10 |
| 2016 | 10 | 10 |
| 2017 | 12 | 11 |
| 2018 | 3 | 13 |
| 2019 | 13 | 15 |
| 2020 | 14 | 7 |
| 2021 | 8 | 16 |
| 2022 | 7 | 18 |
| 2023 | 4 | 20 |
| 2024 | 8 | 15 |
| 2025 | 11 | 22 |
| 2026 | 8 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use8 Sep 2026US 12,729,377 B2Arrowhead Pharmaceuticals, Inc.
- RNAi constructs for inhibiting ASGR1 expression and methods of use thereof1 Sep 2026US 12,723,248 B1Amgen Inc.
- RNAI constructs for inhibiting PNPLA3 expression and methods of use thereof7 Jul 2026US 12,674,166 B2Amgen Inc.
- RNAi agents for inhibiting expression of Beta-ENaC, compositions thereof, and methods of use16 Jun 2026US 12,655,428 B2Arrowhead Pharmaceuticals, Inc.
- Processes for the production of oligonucleotides9 Jun 2026US 12,649,939 B2GlaxoSmithKline Intellectual Property Development Limited
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
- RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use17 Sep 2026US 2026/0275351 A1Arrowhead Pharmaceuticals, Inc.
- Cyclic-disulfide modified phosphate based oligonucleotide prodrugs10 Sep 2026US 2026/0265737 A1Alnylam Pharmaceuticals, Inc.
- Nucleic acid compounds10 Sep 2026US 2026/0265753 A1Tangram Therapeutics PLC
- Nucleic acid compounds27 Aug 2026US 2026/0250672 A1Tangram Therapeutics PLC
Most cited
By later US patents
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- Conjugates and compositions for cellular delivery194US 7,491,805 B2Sirna Therapeutics, Inc. · 2009
- RNA polymerase III-based expression of therapeutic RNAs154US 5,902,880 ARibozyme Pharmaceuticals, Inc. · 1999
- Compositions and methods for inhibiting expression of the PCSK9 gene152US 7,605,251 B2Alnylam Pharmaceuticals, Inc. · 2009
- Interfering RNA molecules134US 7,452,987 B2Silence Therapeutics GmbH · 2008